


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Original) A pharmaceutical composition of matter comprising one or more anticholinergics and one or more PDE-IV inhibitors as active components of the pharmaceutical composition, wherein one or more of the active components may be an enantiomer, a mixture of enantiomers, a racemate, a solvate or an hydrate.
2. (Original) The pharmaceutical composition as recited in Claim 1 wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
3. (Original) The pharmaceutical composition as recited in Claim 1 wherein the active components are present together in a single formulation.
4. (Original) The pharmaceutical composition as recited in Claim 1 wherein the active components are in at least two separate formulations.
5. (Original) The pharmaceutical composition as recited in Claim 1 wherein the anticholinergic is selected from the group consisting of one or more tiotropium salts, one or more oxitropium salts and one or more ipratropium salts.
6. (Original) The pharmaceutical composition as recited in Claim 5 wherein the anticholinergic is one or more tiotropium salts.
7. (Original) The pharmaceutical composition as recited in Claim 1 wherein one or more anticholinergic is present in the form of a chloride, bromide, iodide, methanesulphonate, paratoluene sulphonate or a methyl sulphate.

8. (Original) The pharmaceutical composition as recited in Claim 7 wherein one or more anticholinergics is present in the form of a bromide.
9. (Original) The pharmaceutical composition as recited in Claim 1 wherein one or more PDE-IV inhibitors is selected from among enprofylline, roflumilast, ariflo, Bay-198004, CP-325,366, BY343, D-4396 (Sch-351591), V-11294A, AWD-12-281 and the tricyclic nitrogen heterocycles of general formula 2a



wherein

R¹ denotes C₁-C₅-alkyl, C₅-C₆-cycloalkyl, phenyl, benzyl or a 5- or 6-membered, saturated or unsaturated heterocyclic ring which may contain one or two heteroatoms selected from among oxygen and nitrogen;


R² denotes C₁-C₅-alkyl or C₂-C₄-alkenyl;

R³ denotes C₁-C₅-alkyl which may optionally be substituted by C₁-C₄-alkoxy, C₅-C₆-cycloalkyl, phenoxy or a 5- or 6-membered, saturated or unsaturated heterocyclic ring which may contain one or two heteroatoms selected from among oxygen and nitrogen;

C₅-C₆-cycloalkyl or phenyl or benzyl optionally substituted by C₁-C₄-alkoxy, optionally in the form of their racemates, their enantiomers, in the form of the diastereomers and the mixtures thereof, optionally in the form of their tautomers and optionally the pharmacologically acceptable acid addition salts thereof.

10. (Original) The pharmaceutical composition as recited in Claim 9 wherein one or more of the PDE-IV inhibitors is selected from among enprofylline, roflumilast, ariflo, AWD-12-281 and the tricyclic nitrogen heterocycles of general formula 2a.

11. (Original) The pharmaceutical composition as recited in Claim 1 wherein the weight ratio of the anticholinergic to the PDE-IV inhibitor is about 1:300 to about 50:1.
12. (Original) The pharmaceutical composition as recited in Claim 11 wherein the weight ratio of the anticholinergic to the PDE-IV inhibitor is about 1:250 to about 40:1.
13. (Original) The pharmaceutical composition as recited in Claim 1 in the form of a formulation suitable for inhalation.
14. (New) An inhalable powder comprising both an anticholinergic, tiotropium bromide, and a PDE-IV inhibitor as active components of a pharmaceutical composition, in combination with a pharmaceutically acceptable excipient selected from glucose, arabinose, lactose, saccharose or maltose, wherein the PDE-IV inhibitor is



wherein

R¹ is cyclopentyl,

R² is n-propyl and

R³ is i-propyl, or a pharmacologically acceptable acid addition salt thereof.

15. (New) The inhalable powder as recited in Claim 14 wherein the weight ratio of the anticholinergic to the PDE-IV inhibitor is about 1:300 to about 50:1.

16. (New) The inhalable powder as recited in Claim 15 wherein the weight ratio of the anticholinergic to the PDE-IV inhibitor is about 1:250 to about 40:1.
17. (New) A method for the treatment of asthma which method comprises administering an inhalable powder as recited in claim 14.
18. (New) A method for the treatment of chronic obstructive pulmonary disease or asthma which method comprises administering an inhalable powder as recited in claim 14.